(R)-2-methoxy-N-(1-(naphthalen-2-yl)ethyl)benzamide | 1184301-92-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (R)-2-methoxy-N-(1-(naphthalen-2-yl)ethyl)benzamide
• 英文别名: Substituted Benzamide Derivative, 5c；2-methoxy-N-[(1R)-1-naphthalen-2-ylethyl]benzamide
• CAS: 1184301-92-5
• 化学式: C₂₀H₁₉NO₂
• 分子量: 305.376
• InChiKey: JVMHYDZSVSEQOA-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (R)-(+)-1-(2-萘基)乙胺 、 邻甲氧基苯甲酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 以99%的产率得到(R)-2-methoxy-N-(1-(naphthalen-2-yl)ethyl)benzamide
  参考文献：
  名称：

  Structure-Based Design, Synthesis, and Biological Evaluation of a Series of Novel and Reversible Inhibitors for the Severe Acute Respiratory Syndrome−Coronavirus Papain-Like Protease

  摘要：

  We describe here the design, Synthesis, molecular modeling. and biological evaluation of a series of small molecule, nonpeptide inhibitors of SARS-CoV PLpro. Our initial lead compound was identified via high-throughput screening of a diverse chemical library. We subsequently carried out structure-activity relationship studies and optimized the lead structure to potent inhibitors that have shown antiviral activity against SARS-CoV infected Vero E6 cells, Upon the basis of the X-ray crystal structure of inhibitor 24-bound to SARS-CoV PLpro, a drug design template was created. Our structure-based modification led to the design of a more potent inhibitor, 2 (enzyme IC50 = 0.46 mu M; antiviral EC50 = 6 mu M). Interestingly. its methylamine derivative, 49, displayed good enzyme inhibitory potency (IC50 = 1.3 mu M) and the most potent SARS antiviral activity (EC50 = 5.2 mu M) in the series, We have carried our computational docking studies and generated a predictive 3D-QSAR model for SARS-CoV PLpro inhibitors.

  DOI：

  10.1021/jm900611t

文献信息

• COMPOUNDS AND METHODS FOR TREATING RESPIRATORY DISEASES
  申请人：Ghosh Arun K.

  公开号：US20110269834A1

  公开（公告）日：2011-11-03

  Described herein are compounds and compositions, and methods for using the compounds and compositions, for treating respiratory diseases and illness, such as severe acute respiratory syndrome (SARS).

  本文描述了化合物和组合物，以及使用这些化合物和组合物治疗呼吸道疾病和疾病，如严重急性呼吸综合征（SARS）的方法。
• Nickel‐Catalyzed Asymmetric Synthesis of α‐Arylbenzamides
  作者：Sergio Cuesta‐Galisteo、Johannes Schörgenhumer、Xiaofeng Wei、Estíbaliz Merino、Cristina Nevado

  DOI：10.1002/anie.202011342

  日期：2021.1.18

  A nickel‐catalyzed asymmetric reductive hydroarylation of vinyl amides to produce enantioenriched α‐arylbenzamides is reported. The use of a chiral bisimidazoline (BIm) ligand, in combination with diethoxymethylsilane and aryl halides, enables the regioselective introduction of aryl groups to the internal position of the olefin, forging a new stereogenic center α to the N atom. The use of neutral reagents

  据报道，镍催化乙烯基酰胺的不对称还原氢化芳基化反应产生对映体富集的α-芳基苯甲酰胺。手性双咪唑啉（BIm）配体与二乙氧基甲基硅烷和芳基卤化物结合使用，可以将芳基区域选择性地引入烯烃的内部位置，从而将新的立体中心α锻造到N原子上。使用中性试剂和温和的反应条件可轻松获得抗癌药，SARS-CoV PLpro抑制剂和KCNQ通道开放剂中存在的与药理相关的基序。
• Intermolecular Enantioselective Benzylic C(sp³)−H Amination by Cationic Copper Catalysis**
  作者：Ling Dai、Ying‐Ying Chen、Li‐Jun Xiao、Qi‐Lin Zhou

  DOI：10.1002/anie.202304427

  日期：2023.6.12

  A highly enantioselective intermolecular benzylic C(sp3)−H bond amination by using a chiral cationic copper catalyst and oxidant di-tert-butyl peroxide is reported. This mild, straightforward method can be used to transform an array of feedstock alkylarenes and amides into chiral amines with high enantioselectivities, and it has good functional group tolerance and a broad substrate scope.

  报道了使用手性阳离子铜催化剂和氧化剂二叔丁基过氧化物进行高对映选择性分子间苄基 C(sp 3 )-H 键胺化。这种温和、直接的方法可用于将一系列原料烷基芳烃和酰胺转化为具有高对映选择性的手性胺，并且具有良好的官能团耐受性和广泛的底物范围。
• [EN] COMPOUNDS AND METHODS FOR TREATING RESPIRATORY DISEASES<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR LE TRAITEMENT DES MALADIES RESPIRATOIRES
  申请人：PURDUE RESEARCH FOUNDATION

  公开号：WO2010022355A1

  公开（公告）日：2010-02-25

  Described herein are compounds and compositions, and methods for using the compounds and compositions, for treating respiratory diseases and illness, such as severe acute respiratory syndrome (SARS).
• Structure-Based Design, Synthesis, and Biological Evaluation of a Series of Novel and Reversible Inhibitors for the Severe Acute Respiratory Syndrome−Coronavirus Papain-Like Protease
  作者：Arun K. Ghosh、Jun Takayama、Yoann Aubin、Kiira Ratia、Rima Chaudhuri、Yahira Baez、Katrina Sleeman、Melissa Coughlin、Daniel B. Nichols、Debbie C. Mulhearn、Bellur S. Prabhakar、Susan C. Baker、Michael E. Johnson、Andrew D. Mesecar

  DOI：10.1021/jm900611t

  日期：2009.8.27

  We describe here the design, Synthesis, molecular modeling. and biological evaluation of a series of small molecule, nonpeptide inhibitors of SARS-CoV PLpro. Our initial lead compound was identified via high-throughput screening of a diverse chemical library. We subsequently carried out structure-activity relationship studies and optimized the lead structure to potent inhibitors that have shown antiviral activity against SARS-CoV infected Vero E6 cells, Upon the basis of the X-ray crystal structure of inhibitor 24-bound to SARS-CoV PLpro, a drug design template was created. Our structure-based modification led to the design of a more potent inhibitor, 2 (enzyme IC50 = 0.46 mu M; antiviral EC50 = 6 mu M). Interestingly. its methylamine derivative, 49, displayed good enzyme inhibitory potency (IC50 = 1.3 mu M) and the most potent SARS antiviral activity (EC50 = 5.2 mu M) in the series, We have carried our computational docking studies and generated a predictive 3D-QSAR model for SARS-CoV PLpro inhibitors.